Mathew Cherian

Employment

• Ohio State University Wexner Medical Center Assistant Professor
  2018 - Present
• Washington University in Saint Louis Instructor
  2015 - 2018
• University of North Dakota School of Medicine and Health Sciences - Southeast Campus Clinical Assistant Professor
  2006 - 2008

Education

• Washington University in Saint Louis Post Doctoral Research Fellow
  2012 - 2015
• Washington University in Saint Louis Clinical Fellow in Hematology and Oncology
  2011 - 2012
• Barnes-Jewish Hospital Clinical Fellow in Hematology and Oncology
  2009 - 2010
• Washington University in Saint Louis Post Doctoral Fellow
  2008 - 2009
• University of North Dakota School of Medicine and Health Sciences - Southeast Campus Resident in Internal Medicine
  2004 - 2006
• University of North Dakota School of Medicine and Health Sciences - Southeast Campus Internship in Internal Medicine
  2003 - 2004
• Christian Medical College, Vellore MBBS
  1994 - 2000

Projects & Funding

Projects & funding information is unavailable.

Publications (48)

• Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆
  ESMO Open 2024 DOI: 10.1016/j.esmoop.2024.103973
  +Save
• Depression, Inflammation, and Intestinal Permeability: Associations with Subjective and Objective Cognitive Functioning throughout Breast Cancer Survivorship
  Cancers 2023 DOI: 10.3390/cancers15174414
  +Save
• Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model
  JCO Clinical Cancer Informatics 2023 DOI: 10.1200/CCI.22.00164
  +Save
• Typhoid vaccine does not impact feelings of social connection or social behavior in a randomized crossover trial among middle-aged female breast cancer survivors
  Brain, Behavior, and Immunity 2023 DOI: 10.1016/j.bbi.2022.09.021
  +Save
• Augmentation of Extracellular ATP Synergizes With Chemotherapy in Triple Negative Breast Cancer
  Frontiers in Oncology 2022 DOI: 10.3389/fonc.2022.855032
  +Save
• Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4/6 inhibitor use
  Journal of the American Academy of Dermatology 2022 DOI: 10.1016/j.jaad.2021.04.092
  +Save
• Distress Disorder Histories Relate to Greater Physical Symptoms Among Breast Cancer Patients and Survivors: Findings Across the Cancer Trajectory
  International Journal of Behavioral Medicine 2022 DOI: 10.1007/s12529-022-10115-4
  +Save
• Breast cancer survivors’ typhoid vaccine responses: Chemotherapy, obesity, and fitness make a difference
  Brain, Behavior, and Immunity 2022 DOI: 10.1016/j.bbi.2022.03.019
  +Save
• Augmentation of extracellular ATP synergizes with chemotherapy in triple negative breast cancer
  bioRxiv 2022 DOI: 10.1101/2022.01.11.475873
  +Save
• Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
  bioRxiv 2022 DOI: 10.1101/2022.01.14.476328
  +Save